neflamapimod
Jump to navigation
Jump to search
Indications
- investigational agent for treatment of Alzheimer's disease
Mechanism of action
- oral inhibitor of the enzyme p38 MAP kinase alpha
More general terms
References
- ↑ Idrus AAI EIP Pharma nabs $20.5M to push Alzheimer's drug through phase 2. FierceBiotech. May 16, 2018 https://www.fiercebiotech.com/biotech/eip-pharma-nabs-20-5m-to-push-alzheimer-s-med-through-phase-2